Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory (R/R) regimens. In first-line therapy, the synergy between ICIs and chemotherapy may surpass the previous standards of AB...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Charles J. Milrod, Ari Pelcovits, Thomas A. Ollila
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-04-01
Serija:	Frontiers in Oncology
Teme:	Hodgkin lymphoma immune checkpoint inhibitors biomarkers survival endpoints clinical trials
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1397053/full
Oznake:	Označite Brez oznak, prvi označite!